F-star Therapeutics

F-star Therapeutics Inc is a biotechnology company developing tetravalent bispecific antibodies for a paradigm shift in cancer therapy. By developing medicines that seek to block tumour immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.In March 2016, the company opened a new facility in the Eddeva building on the Babraham Research Campus in Cambridge, UK.In March 2008, f-star planned to open a research facility in Cambridge, UK, in April 2008. By May 2012, all research operations had been brought together in Cambridge, UK.In March 2023, invoX Pharma Ltd acquired F-star Therapeutics Ltd.On November 2020, F-star Therapeutics completed the business combination with Spring Bank Pharmaceuticals.In August 2020, Spring Bank Pharmaceuticals had entered into an agreement with F-star Therapeutics limited, as a definitive share exchange agreement, following which Spring Bank subject to stockholder